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Trial Designs 
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Abstract  
Background  
Current guidelines on the use of β-blockers in post-acute myocardial infarction (MI) patients 
without reduced left ventricular ejection fraction (LVEF) are based on studies before the 
implementation of modern reperfusion and secondary prevention therapies. It remains 
unknown whether β-blockers will reduce mortality and recurrent MI in contemporary 
revascularized post-MI patients without reduced LVEF.  
Design 
BETAMI is a prospective, randomized, open, blinded end-point (PROBE) multi-center study 
in 10,000 MI patients designed to test the superiority of oral β-blocker therapy, compared to 
no β-blocker therapy. Patients with LVEF ≥40% following treatment with percutaneous 
coronary intervention or thrombolysis and/or no clinical signs of heart failure are eligible to 
participate. The primary end-point is a composite of all-cause mortality or recurrent MI 
obtained from national registries over a mean follow-up period of 3 years. Safety end-points 
include rates of non-fatal MI, all-cause mortality, ventricular arrhythmias, and hospitalizations 
for heart failure obtained from hospital medical records 30 days after randomization, and from 
national registries after 6 and 18 months. Key secondary endpoints include recurrent MI, heart 
failure, cardiovascular and all-cause mortality, and clinical outcomes linked to β-blocker 
therapy including drug adherence, side-effects, cardiovascular risk factors, psychosocial 
factors, and health economy. Statistical analyses will be conducted according to the intention-
to-treat principle. A pre-specified per-protocol analysis (patients truly on β-blockers or not) 
will also be conducted. 
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Conclusions 
The results from the BETAMI trial may have the potential of changing current clinical 
practice for treatment with β-blockers following MI in patients without reduced LVEF. 
EudraCT number 2018-000590-75. 
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Background  
β-blockers have been used in long-term secondary prevention following acute myocardial 
infarction (MI) irrespective of its severity following publication of the pertinent landmark 
studies in the 1980s.
1-3
 Since then, implementation of acute coronary 
reperfusion/revascularization, introduction of high-sensitive troponins, and the use of modern 
secondary preventive treatments
4
 have changed both the MI diagnostics and the short and 
long-term prognosis for MI patients.
5,6
  
 
Current international guidelines on the management of coronary heart disease therefore call 
into question the efficacy of β-blockers in contemporary post-MI patients without heart 
failure, and the strength of recommendations differs across diagnosis and continents.
7-10
 The 
European Society of Cardiology (ESC) 2017 STEMI guidelines recommend β-blockers to be 
started in-hospital and continued long-term following MI, with a class IIa level of evidence B 
recommendation.
7
 In the ESC 2015 guidelines for NSTEMI, early β-blocker therapy has a 
class I, level B recommendation for patients with persistent ischemic symptoms whereas there 
is no clear recommendation for long term β-blocker treatment in patients without heart failure. 
8
 Recent American Heart Association guidelines recommend β-blockers as a class I indication 
for all patients with STEMI who do not have a contraindication,
11
 and as class IIa indication 
for patients with NSTEMI and a normal left ventricular function.
10
  
 
The only randomized large-scale β-blocker trial conducted in recent years,
12
 two large meta-
analyses of randomized, controlled trials,
13,14
 and a large US registry study using propensity 
score analysis
15
 failed to verify the short (30 days) and long-term (≥ 12 months) survival 
benefit of β-blockers in contemporary post-MI patients without heart failure that was 
observed in the older studies. In a recent systematic review and meta-analysis of observational 
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studies in nearly 200 000 contemporary post-MI patients where the majority did not have 
heart failure or reduced LVEF, we found that β-blocker treatment was associated with a 26% 
reduction in all-cause mortality a after median follow-up time of 2.7 years.
16
 However, when 
controlling for study bias, particularly the effect of small studies, the association between β-
blocker therapy and mortality disappeared.  β-blockers did reduce rates of recurrent MI and 
angina in the studies from the reperfusion era in the meta-analysis from Bangalore et al,
13
 but 
the benefit appeared to be short term (30 days) and at the expense of increase in heart failure, 
cardiogenic shock, and drug discontinuation. Notwithstanding, patients experiencing heart 
failure or arrhythmias following an MI have an unquestionable indication for treatment with 
β-blockers.
17,18  
 
The β-blocker doses used in current clinical practice
19,20,21 
are lower than used in the landmark 
trials.
1-3
 Unfortunately, information about β-blocker types, doses, persistence and new 
prescriptions are lacking in most prospective cohort studies conducted in the post-
revascularization era.
16
 Furthermore, studies comparing the effect of high vs. low β-blocker 
doses on cardiac outcomes report conflicting results.
19,20,21
 Randomized clinical trials are 
therefore needed to investigate the effect of β-blocker doses for cardiac prognosis.  
 
In a recent Norwegian nationwide study, 82% of post-MI patients received β-blockers at 
discharge, a figure that only decreased by 5%  after 12 months follow-up.
22
 Similar estimates 
are reported internationally, but with large variations between countries.
23
 Whilst β-blockers 
are considered relatively safe and inexpensive, they do have well-known and common side 
effects
1-3
 that may have deteriorating effect on quality of life, functional status, and health 
economic aspects such as the ability to work and health-care utilization. Furthermore, 
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adherence to other (potentially more efficacious) secondary preventive medications may 
diminish as a result of concomitant use of β-blockers.
24
  
 
In both current clinical practice guidelines and contemporary studies there is at present a 
questionable rationale for β-blockers and the important question arises whether β-blocker 
treatment still improves clinical outcome in contemporary revascularized post-MI patients 
without reduced LVEF.  
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Study design and methods  
Study objectives and hypothesis 
The primary objective is to test whether oral β-blocker therapy reduces the risk of all-cause 
mortality or non-fatal MI compared to no such therapy, in post-MI patients without reduced 
LVEF. The working hypothesis is that 'β-blocker treatment’ is still superior to 'No β-blocker 
treatment' in such patients in terms of all-cause mortality and recurrent MIs over an average 
follow-up period of 3-years.  
 
The key secondary objectives are to study whether β-blocker therapy reduces the risk of each 
of the primary end-points separately, risk of cardiovascular (CV) death, and risk of 
hospitalization for ventricular arrhythmias or heart failure compared to no such therapy.  
Furthermore, to assess clinical outcomes linked to β-blocker therapy including outcomes in 
treatment subgroups (i.e. dose tertiles), LVEF subgroups (preserved LVEF: ≥50% vs. mid-
range LVEF: 40-49%), drug-related side-effects, drug adherence, cardiovascular risk factors, 
quality of life, anxiety, depression, symptom burden (angina, dyspnea), sexual dysfunction 
and sleep disturbance. A cost-utility analysis of treatment with β-blocker therapy in relation to 
quality of life and a health economic evaluation including drug use, health care utilization, 
employment, income, and benefit take-up will also be conducted. 
 
Exploratory biobanking objectives include direct determination of the proportion and 
predictors of non-adherence with β-blockers, statins and other cardiovascular drugs assessed 
by liquid chromatography-tandem mass spectrometry (LC-MS/MS) methods quantifying drug 
concentrations in blood.  Pharmacokinetic, pharmacodynamic and pharmacogenetic markers 
associated with side-effects and suboptimal response to treatment with β-blockers and other 
cardiovascular drugs will also be explored. 
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Study design 
This is a prospective, randomized, open, blinded end-point (PROBE) superiority multi-center 
study conducted in Norway. The study flow chart is shown in Figure 1. In all, 10,000 patients 
will be included from ten participating centers (n=8 with PCI, n=2 without PCI). Reperfusion 
therapy is defined as primary PCI or thrombolysis for STEMI, and “early” PCI (i.e. during 
index hospitalization) for NSTEMI. Patients will be electronically randomized to open 
prescription of a β-blocker or no such treatment. All other documented secondary 
prophylactic drugs will be prescribed according to existing guidelines
4
 as judged by the 
responsible attending physician.  
 
Oslo University Hospital (OUH) is the sponsor for this investigator-initiated trial. Center of 
Regional Research Support (CRRS), OUH is the clinical and data coordinating center. The 
trial has received grant support from the Health South-East research program in Norway 
(grant number 2017205). Other than mediating financial support, the sponsor is not involved 
in the conduction of this study.  The Steering Committee (SC), comprising representatives 
from all PCI-centers and selected non-PCI centers in Norway in cooperation with CRRS 
including Statisticians at Oslo Center of Biostatistics and Epidemiology (OCBE) are the 
responsible bodies for the design and execution of the trial, related statistical analyses, and all 
aspects of manuscript preparation, including drafting and editing of the paper and its final 
content.  
 
Study population, entry criteria, and inclusion procedures 
 
All patients with a first or recurrent MI treated with PCI or thrombolysis will be screened for 
eligibility. PCI procedures will be performed according to standard operating procedures at 
the treating hospitals.
7-10
 Inclusion and randomization of the patients will be performed at PCI 
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centers and selected high-volume community hospitals within 8 days following PCI or 
thrombolysis. A prerequisite for participation is that there is no clinical sign of heart failure at 
the time of randomization according to the assessment of the responsible physician, and that 
LVEF is estimated to be ≥40% by an echocardiographic examination.  Previous treatment 
with a β-blocker is not an exclusion criterion for study enrolment. Based on data from a recent 
Norwegian post-MI study,
25
 we expect that this sub-group will comprise 10-15% of the total 
sample population. Patients can participate in any other study that does not directly alter the 
effect of β-blocker treatment. Further details on inclusion and exclusion criteria are 
summarized in Table 1. 
 
Randomization and interventions with study drug (dosage and administration)  
If all eligibility criteria are met and written informed consent is provided, patients will be 
electronically randomized to open prescription of β-blocker or no such treatment in a 1:1 
ratio. Block randomization (with block sizes 4, 6, and 8 in random order), stratified by study 
centre will be conducted online (http://www.betami.org.) through a web-based application.  
 
Prescription of the dose and type of β-blocker therapy will be left at the discretion of the 
community site physician.  Accepted generic drug and dosages include; metoprolol succinate 
up to a total dose of 200mg daily, bisoprolol up to a total dose of 10mg daily or carvedilol up 
to a total dose of 50mg daily. In general, doses >100mg OD of metoprolol ret/equivalence 
dose of the other three β-blockers will be recommended when clinically tolerated. Patients 
will be encouraged to continue the prescribed β-blocker until the end of the study. Patients 
randomized to no β-blockers will be discouraged to use β-blocker therapy as long as there is 
no other indication than strictly secondary prevention after MI.  
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All study patients will receive a BETAMI information letter (ID-card size) stating that they 
participate in a clinical trial, containing information about the sponsor and contact information 
to the local Primary investigator (PI) and study nurse in addition and to a Central Study 
Monitor (CSM) at the CRRS, as well as the treatment allocation. Patients will be instructed to 
wear the ID-card in case of medical contact or primary care visits that may influence 
adherence to treatment.  
 
Data collection and monitoring 
A detailed overview of data collected at baseline, during the treatment follow-up period, and 
at the study-end is shown in Table 2. Baseline data will be obtained from hospital records and 
discharge letters (medication, comorbidity, cardiac rehabilitation, and blood pressure, weight 
and height measurements) echocardiographic examinations, and a self-report questionnaire 
about lifestyle behavior, psychosocial factors and quality of life. Relevant standard blood 
samples (i.e. hematology, clinical chemistry and lipids) will be analyzed at community site 
hospitals. In addition, blood samples from a random subsample of 2500 patients will be sent 
to the central laboratory for inter-laboratory validation, analyses of cardiovascular biomarkers 
and pharmacokinetic, pharmacodynamic and pharmacogenetic markers, as well as biobanking 
for future research. The echocardiographic records will be analysed for a variety of functional 
and prognostic parameters. 
 
At 30 days following randomization and every 6 months thereafter until the end of study, an 
eCRF will be made available for the patients to complete. An SMS reminder will be issued in 
case of missing responses. Paper version of the questionnaires will be available and sent by 
post to those who do not respond. The forms will include brief screening questions covering i. 
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status on β-blocker treatment, ii. concomitant treatment with antiplatelets, and statins, iii. 
lifestyle behavior, drug adherence, and perceived CV drug related side-effects, iv. 
participation in cardiac rehabilitation and other secondary preventive follow-up visits, v. 
screening questions on generic health status, depression, anxiety, muscle pains, fatigue, sexual 
dysfunction, and insomnia. These symptoms are known side-effects to both β-blocker therapy 
and other CV drugs as well as common complications to the MI itself. Study participants will 
not be informed that these symptoms could be β-blocker side-effects to prevent that the lack 
of placebo drug effect will influence the patient’s response to these questions.  To further 
minimize this risk, the mean score for each item during follow-up will be used in the final 
analyses.  
 
Each study site will be monitored regularly by the CSM / CRRS according to Good Clinical 
Practices standards. 
 
Safety monitoring and reporting 
Thirty days after randomization, all patients will be contacted by telephone by specially 
trained study personnel and interviewed after a standardized written protocol for occurrence 
of events since discharge with emphasis on hospitalizations for subsequent cardiovascular 
events. Hospital records will be screened for the safety end-points (i.e. rate of ECG-
documented ventricular arrhythmias, hospitalization for heart failure, recurrent MI or all-
cause mortality) by the local study nurse and/or site- PI if patients a) report hospitalization for 
cardiovascular events or b) if the patients do not respond to the phone call. Further safety 
monitoring will be based on rates of recurrent MI and all-cause death obtained from the 
Norwegian CV Disease Registry and the Population Registry after 6 and 18 months follow-
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up. In addition, the PIs at each participating center are responsible for reporting Serious 
Adverse Events (SAEs) and Suspected Unexpected Serious Adverse Reactions (SUSARs) to 
the DSMB according to good clinical practice and the requirements put forward by the 
Norwegian Medicines Agency. 
 
A sub-sample of 2500 patients from both treatment arms will be invited to a subsequent visit 
at the hospital outpatient clinic after 6 months follow-up to repeat the baseline examination, 
the self-report questionnaire, and collect blood samples for analyses of drug-related 
biomarkers and concentrations of β-blockers and other cardiovascular drugs.  
 
Outcome measurements and definitions 
Patients will be followed up for a minimum of 2 years, giving a likely mean follow-up of 3 
years (range 2-4 years), with regard to the primary and secondary endpoints described in 
Figure 1. Assessment of the primary outcome will be obtained from the Norwegian 
Population Registry and the Norwegian Myocardial Infarction Registry at study end. 
Assessment of the other secondary study end-points will be ascertained through 
administrative registries (income, social security micro data, healthcare utilization, drug 
prescription) and clinical CV disease (myocardial infarction, heart failure, arrhythmia, 
coronary angiography) registries and the Cause of Death registry. All these registries have a 
mandatory reporting system (no attrition), and a unique personal identifier enables us to link 
the study participants to the registries.  
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Statistical considerations  
Sample size  
Sample size calculation was made for the primary endpoint which is a composite of all-cause 
mortality or recurrent MI. Incidence rates were obtained from the NORSTENT trial
26
 
indicating a 3-year event rate of 11% for the primary endpoint in the MI-population (all-cause 
mortality 4.5% and recurrent MI 7.5%). Assuming a recruitment period of 2.5-3 years, a 3-
year mean follow-up period, and a randomization ratio of 1:1, a sample size of 7940 patients 
(794 events) will provide a power of 80% to detect a relative risk reduction of approximately 
20% (11% primary endpoints with no β-blocker treatment vs 9% primary endpoints with β-
blocker treatment; hazard ratio of 1.22). Based upon estimated drop-out rates we expect 
crossover between groups in the range of 10-15%, particularly from the β-blocker group to 
the non- β-blocker group. In addition, expected withdrawals will be cases where non-β-
blocker group patients require β-blocker-treatment for other emerging indications. Also, we 
allow for a slightly lower overall event rate (9% instead of 10%), such that the total sample 
size of the trial will be 10 000 patients (5000 per treatment group). 
 
Statistical analyses  
The primary statistical analyses will be conducted according to the intention-to-treat (ITT) 
principle. A secondary/sensitivity analysis will be performed on the per protocol (PP) set of 
patients (patients truly on β-blockers or not). OCBE will be responsible for the statistical 
quality of the trial. The primary endpoint is time to all-cause mortality or non-fatal MI, 
assessed after all patients have completed a minimum of 2 years follow-up. The null 
hypothesis is that the rate of all-cause mortality or MI in the β-blocker group is equal to the 
rate in the group without β-blocker, whereas the alternative hypothesis (two-sided) is that the 
rate of all-cause mortality or MI in the group with β-blocker is greater than or smaller than the 
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rate in the group without β-blocker. A Cox regression model will be used with prescription of 
β-blocker (yes/no) and study site as covariates since these factors were used to stratify the 
randomization. A hazard ratio for prescription of β-blocker vs no β-blocker with a 95% 
confidence interval will be estimated, and a test of a hazard ratio equal to one will be 
performed. The survival curves for the two groups (β-blocker vs no β-blocker) will be 
estimated and plotted with the Kaplan-Meier estimator and the equality of the survival curves 
will be tested with the log-rank test.  
 
Secondary endpoints will be analyzed in a similar manner as the primary endpoints, with Cox 
regression models and Kaplan-Meier survival curve estimation or other suitable statistical 
methods detailed in the statistical analysis plan (SAP). Other exploratory analyses of primary, 
secondary, and exploratory variables, on the whole trial sample or in selected subgroups, may 
be performed if appropriate. The decision to perform such analyses will be made by the 
executive steering committee. 
 
 
Safety analysis  
After 1/3 (n=3334) and 2/3 (n=6668) of the patients, respectively, have completed 30 days 
follow-up, the Data and Safety Monitoring Board (DSMB) will analyze the 30-days safety 
endpoint. The DSMB will recommend to the executive steering committee that the trial is 
stopped if one of the treatment arms has 50% more events than the other. A 95% Koopman 
confidence interval for the ratio of probabilities, defined such that the ratio is above 1.0, will 
be estimated. If the lower confidence limit exceeds 1.5, the stopping criteria will be deemed to 
have been met, triggering a recommendation from DSMB to steering committee (SC) to stop 
the study. 
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The safety endpoint of non-fatal MI and all-cause mortality, to be assessed at 6 and 18 months 
by the DSMB, will not be subjected to a pre-defined stopping criterion. The recommendation 
to either continue or stop the trial because of an unbalance in MI and mortality between the 
treatment arms will be at the discretion of the DSMB. 
 
Study organization  
Steering committee and data safety monitoring board  
The National SC composed of the study chair (DA) and co-chair (JM), work-package leaders 
(TD, KHH, NTV, JM, MWF), and the PIs of the participating centers approved the study 
design, protocol, and amendments issued to the DSMB and the participating centers. The 
DSMB consisting of three international experts will overview safety and will have access to 
unblinded data. The DSMB provides advice on modifying or stopping the study as needed. 
However, the final decisions regarding changes in the study protocol remain in the hands of 
the SC. The DSMB members will not be a part of the study organization and must not have 
any competing interests as judged by the SC  
 
Clinical end-point committee (CEC) and adjudication 
Adjudication of safety-points at 30 days follow-up according to pre-specified and 
standardized criteria will be performed by a CEC blinded to study assignment. The CEC will 
not evaluate the primary study endpoints at study end since these are directly derived from the 
Norwegian Population Registry and the Norwegian Myocardial Infarction Registry which are 
valid and reliable.
27
 The interrater reliability for STEMI and NSTEMI diagnoses obtained 
from the Norwegian Myocardial Infarction Registry were excellent (agreement coefficient 
>0.95) compared to hospital medical records reviews by experienced audit nurses blinded to 
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the registry data.
27
 Both registries are also complete
28
 due to the mandatory reporting system 
and the personal identity numbers given to all citizens in Norway. The secondary study 
outcomes obtained from administrative and clinical CV disease registries with lower validity 
and completion rates will be adjudicated with hospital medical records at study-end by CEC 
blinded to the registry data.  
 
Data coordination and site management 
Data collection, coordination will be under the responsibility of the CRRS.  Continuous site 
monitoring will be performed by a CSM engaged by the CRRS in cooperation with the SC.   
 
Ethical and other regulatory approvals 
The study will be conducted in accordance with the Declaration of Helsinki and are consistent 
with ICH/Good Clinical Practice and applicable regulatory requirements. All patients must 
provide written informed consent. Registration of patient data will be carried out in 
accordance with national personal data laws. The study protocol, including the patient 
information and informed consent form has been approved by the Joint Regional Ethics 
Committee in Norway (number 2018/455) and the National Medicines Agency (number 
18/02571-6). The trial protocol has been registered at the European Clinical Trials Database 
(EudraCT) (number 2018-000590- 75) and at http://register.clinicaltrials.gov (number 2018-
000590-75). 
 
Trial status and timeline 
In Norway approximately 12 500 patients have a MI each year, of whom approximately 65% 
are treated with PCI (a minority with thrombolysis for STEMI), and hence are theoretically 
eligible for study participation.
28
 Based on the study inclusion and exclusion criteria and 
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previous experience with patient inclusion in similar randomized trials, a conservative 
estimate is that 10,000 patients may be enrolled over a 2½ - 3-year period. The first patients 
will be enrolled on October 1
st
 2018. With an inclusion duration of three years, the mean 
follow-up time at end of inclusion is approximately 1.5 years; hence, the subsequent follow-
up period will be approximately 2 years and will last until all patients have completed a 
minimum of 2 years follow-up. The total study duration from inclusion of the first patient to 
completion of the last included will be 4½ years. Thus, the final results of primary endpoint 
are expected in March 2023.  
 
Scandinavian collaboration -joint analysis of BETAMI, REDUCE-SWEDEHEART, and 
DANBLOCK 
A large number of patients is needed to identify the benefits of β-blockers in patient (i.e. 
men/women, young/elderly) and treatment (β-blocker doses) subgroups and to resolve the 
question of all-cause mortality. The REDUCE-SWEDEHEART in Sweden 
(ClinicalTrials.gov Identifier: NCT03278509) is to our best knowledge, the only ongoing 
randomized controlled β-blocker trial on contemporary post-MI patients without heart failure. 
REDUCE- SWEDEHEART is also designed as a superiority trial and will include 7000 
patients with comparable entry criteria and equal primary study end-point to BETAMI. A 
similar superiority trial in Denmark (DANBLOCK) has been designed and is currently 
seeking funding. 
 
After completion of the primary analyses of the Scandinavian trials, a pre-specified post-trial 
joint analysis of data is planned. Together, these trials will comprise at least 17,000 patients. 
We then have a power of 79% to detect a relative difference between the treatment groups in 
all-cause mortality of approximately HR=1.22 (event rates: 4.5% vs 3.7%). The power to 
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detect the same relative difference in recurrent MI is 94% (event rates: 7.5% vs 6.1%). The 
increased power and precision of this joint analysis facilitates clinical decision making on 
both primary and secondary endpoints, in addition to increased generalizability through a 
broader patient population.  
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Discussion 
The BETAMI trial will provide definitive evidence on the effects of oral β-blocker therapy on 
all-cause mortality and recurrent MI in revascularized post-MI patients without reduced LV 
function. This is an important clinical issue because of the lack of scientific evidence for a 
treatment prescribed to most patients with one of the leading chronic diseases worldwide.
29 
The varying prescription rates of β-blockers and the potential negative consequences of side-
effects for drug adherence, quality of life, functional status and social and economic aspects, 
further encourage a scientific re-evaluation of the potential benefits or risks associated with 
current clinical practice.  
 
The three old landmark trials demonstrated a significant 28-40% relative reduction of all-
cause mortalities in patients treated with β-blockers.
1-3
 Two of these studies also found a 
16%
1
 and 30%
3
 reduction in occurrence of re-infarctions, respectively. Only the BHAT trial 
evaluated the incidence of a new diagnosis of heart failure and could not show any difference 
between propranolol and placbo.
1
 No previous studies have shown any prophylactic effect of 
β-blockers on the development of subsequent heart failure among patients without heart 
failure at baseline. A superior design with the composite outcome all-cause mortality or 
recurrent MI has therefore been chosen for the present study. In line with another large trial 
conducted the past years,
30
 we have chosen a PROBE design which makes the study more 
practically and economically feasible than a double blinded placebo-controlled study. An 
inevitable limitation with PROBE design is that the lack of placebo in itself introduces a 
theoretic over-estimation of β-blocker`s effect on the patient reported outcomes during 
follow-up, since no effect inherent to placebo tablets will be amenable to subtraction from the 
active drug study arm.   
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BETAMI will be a pragmatic study and patient recruitment and baseline registrations will be 
conducted as part of routine clinical practice. Patients previously treated with β-blockers will 
also be included to increase the generalizability of the study results and to reduce the total 
inclusion time.  Norway is well experienced with and has a good infrastructure for running 
large multicenter studies and the estimated inclusion rate in BETAMI is in line with the rate 
in recent nationwide post-MI trial.
26
 Thus, the estimated inclusion period of 2.5-3 years 
appears feasible.      
 
Dosages used in the pivotal β-blocker trials were very high (i.e. about 80% of the patients had 
taken more than 90% of the prescribed target doses), and do not reflect contemporary 
practice.
1-3
 In Norwegian revascularized post-MI patients without heart failure, the prescribed 
dosages equipotent to metoprolol succinate over the first 12 months ranged 25-100 mg (mean 
60mg) daily.
22
  Treatment with suboptimal β-blocker doses could therefore potentially partly 
explain why the beneficial effects of β-blocker are not reproduced in observational studies 
conducted in the post-revascularization period.
12-15,16 
The impact of β-blocker doses on 
cardiac outcomes has recently been addressed in several observational studies.
19,20,21
 Whereas 
lower one-year in-hospital mortality following MI was observed in patients treated with ≥50% 
vs. <50% of the β-blocker target doses in one study,
19
 two other studies
20,21
 found no benefits 
on survival or cardiac outcomes in patients treated with  β-blocker doses approximating those 
used in the landmark trials compared with lower doses. An important caveat for these findings 
is that they do not represent randomized clinical trial results. Since there is, at present no firm 
rationale for the optimal β-blocker dose in contemporary post-MI patients without heart 
failure or reduced LVEF, we have chosen a pragmatic dosage recommendation that reflects 
contemporary management, for which this study is designed to test; There will not be a 
defined minimum dosage, and the decision about the β-blocker dosage is left up to the 
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discretion of the treating physicians. However, it will be recommended to aim for doses 
>100mg OD of metoprolol ret/equivalence when clinically tolerated. This will, to our opinion, 
contribute to an adequate β-blocker dose in the intervention arm across the participating 
centers. 
 
Most studies showing improved outcome with β-blockers have been conducted in patients 
with symptomatic heart failure and LVEF <40%, who have already been treated with an 
angiotensin-inhibitor. 
14
 In the present study patients with a clinical diagnosis of heart failure 
will be excluded. The cut-off value introduced for LVEF has been a matter of debate; 
especially since the ongoing REDUCE trial will only include patients with LVEF ≥50%. Such 
a high level will inevitably reduce inclusion rates but concerns of safety have been raised for 
selecting the lower level of ≥40%. In a recent meta-analysis of PCI-treated patients with 
STEMI and preserved LVEF, however, Misumida et al
31
 found no differences in a favorable 
mortality outcome of β-blockers versus no β-blockers in a subgroup analysis stratified 
according to the definition of LVEF being >40% or >50%. In a large recent UK registry 
study
15
, where patients with a diagnosis of heart failure had been carefully excluded, no 
differences in lack of mortality reduction were found among patients with LVEF ≥50% versus 
all patients who had LVEF measured, with a cut-off level of ≥30%. (B. Dondo, personal 
communication). Recently, a meta-analysis of randomized trials of β-blockers in heart failure 
reported an insignificant mortality reduction in patients with mid-range LVEF (40-49%), but 
this finding was based on only 570 randomized patients as opposed to a highly significant 
mortality benefit among 13355 patients with reduced  LVEF (< 40%).
14
 By introducing a cut-
off value of ≥40%, the BETAMI study gives a valuable opportunity to evaluate patients 
without reduced LVEF and stratify patients with mid-range (i.e. LVEF 40-49%) vs. preserved 
LVEF (i.e. LVEF ≥ 50%) for clinical outcome in post-MI patients without clinical evidence of 
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heart failure. It is well known that a left ventricular ejection fraction (EF) below 35-40% is an 
precise predictor of mortality, but does not have similar predictive value above 40%.
32
 We 
have previously shown that a modern echocardiographic technique, left ventricular global 
longitudinal strain (GLS) has superior accuracy for prognostic information compared to 
traditional measures when LVEF is above 40%.
33
  A BETAMI sub-study  including 
traditional and modern echocardiographic methods will be analysed for myocardial function 
and prognostic information.  
 
 
The use of β-blockers is associated with well-known potentially serious side-effects such as 
hypotension, and bradyarrhythmia’s.
1-3
 The potential risk of participating in BETAMI is 
therefore related to the risk of adverse cardiovascular events in the study patients who do not 
receive β-blockers, including those with established CVD who are taken off their β-blockers 
at inclusion. Recently, Puymirat et al
34
 reported that early β-blocker use in post-MI patients 
was associated with reduced 30-day mortality, based upon propensity score matched cohorts 
comprising 502 patients in each group. However, discontinuation of β-blockers after one year 
was not associated with different five-year survival. In a large recent registry study of post-MI 
patients without heart failure, Dondo et al
15
 did not observe any mortality benefit from β-
blocker versus non- β-blocker after 30 days, 6 or 12 months in a propensity analysis 
comprising 16 683 patients. The strict study inclusion and exclusion criteria, the planned 
safety analyses based on a careful adverse event monitoring after 30 days follow-up and after 
6 and 18 months in addition to the predefined termination criteria are pursued in order to 
mitigate the risk of study participation.  
 
Other side-effects of β-blockers reported in the landmark trials include fatigue, dyspnea, 
depressive symptoms, sexual dysfunction, sleep disorders, muscle pains, cold hands and feet, 
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and weight gain.
1-3
 Not all these side-effects are supported by evidence from randomized 
trials, e.g. the association between β-blocker and depression and insomnia, respectively, has 
yet to be proven. The comprehensive and interdisciplinary data collection from clinical 
examinations, e-questionnaires and valid administrative and national registries will provide 
unique longitudinal outcome data linked to β-blocker therapy. The biobank data will provide 
new knowledge on how altered drug metabolism due to genetic polymorphisms, and/or drug-
drug interactions, potentially reduce or increase the concentrations (and thus the effects) of β-
blockers in blood leading to side-effects or poor treatment response
35
. Altogether, the 
evidence from the cardiovascular, pharmacological, genetic, biomarker, and psychosocial sub-
studies may be useful in personalizing secondary prevention and modelling effective and 
sustained interventions
36
 that may potentially reduce the burden of side-effects,
37
 improve 
drug adherence,
38
 CV risk factor control and cardiac prognosis. The health economic 
evaluation of costs and benefits related to β-blockers and other secondary preventive drugs 
will potentially be of importance for future treatment decisions, healthcare providers and 
authorities.
39
   
 
Conclusion  
The results from the BETAMI trial together with the ongoing similar REDUCE-Swedeheart 
study and the planned DANBLOCK trial will potentially change present clinical practices for 
treatment with β-blockers following MI in patients without heart failure or reduced LVEF. 
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Figure 1 BETAMI Study flowchart  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MI treated with early PCI or thrombolysis. 2 ½ -3 years enrollment period (n=10,000) 
Exclusion criteria  
 Having a condition requiring β-
blockers  
 Contraindications to β-blockers 
 Any condition/situation that put 
subjects at risk or 
interfere/confound study results  
      
Randomized 1:1 day 1-8 at the PCI centers or community hospitals 
β-blocker therapy (n =5000) 
(Aim for doses >100mg OD of 
metoprolol ret/equivalence dose) 
No β-blocker therapy (n =5000) 
Primary:  
 Time to all-cause mortality or non-fatal MI  
Secondary:  
 Time to non-fatal MI, all-cause mortality, ventricular arrhythmias, 
hospitalization for heart failure, cardiovascular death  
 Income, employment status, drug use, healthcare utilization, benefit 
take-up 
 Cardiovascular risk factors, drug-adherence, drug related side-
effects, quality of life, and psychosocial factors 
Safety: 
 Rate of non-fatal MI, all-cause mortality, ventricular arrhythmias, 
and hospitalization for heart failure 30 days after randomization  
 Rate of non-fatal MI and all-cause mortality after 6 and 18 months  
Exploratory: 
 Pharmacokinetic, pharmacodynamic and pharmacogenetic markers 
associated with side-effects and suboptimal response to treatment 
with β-blockers 
 Sociodemographic, clinical and psychosocial factors 
 
 
 
Baseline study data  
 Hospital record 
 Self-report questionnaire  
 Biobanking on a subgroup (n=2500) 
 
 
      
Study data during treatment period of mean 3 
years  
 
 Electronic patient self-report questionnaires  
 Retrospective linkage to national registries 
 Clinical data and biobanking at 6 months on a 
subgroup (n=2500)  
 
Safety: 
 Telephone contact and hospital medical record 
screening at day 30 and at study-end 
 Linkage to the Norwegian Cardiovascular 
disease registry and the Population Registry 
after 6 and 18 months follow-up  
 Regular screening for SAE/SUSARs based on 
hospitalizations at local hospitals  
  
Other treatment and follow-up care as usual 
BETAMI organization and study nurse for safety-issues 
 
Primary study endpoints 
 Norwegian Population Registry 
 Norwegian Myocardial Infarction Registry 
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Table 1 Enrollment criteria  
 
 
 
 
 
 
 
 
 
 
Inclusion criteria (all the following) 
 18 years or older 
 Diagnosed with an acute MI type I according to the "Universal Definition of MI" (Defined as a detection of a rise 
and/or fall of cardiac biomarker value, preferably troponin, with at least one value above the 99
th
 percentile upper 
reference limit and with at least one of the following; a) symptoms of ischemia, b) new or presumed new 
significant ST-segment-T wave changes or new left bundle branch block, c) development of pathological Q 
waves, d) imaging evidence of new loss of viable myocardium or e) identification of an intracoronary thrombus 
by CAG)  
 Must have been treated with PCI for culprit-lesion or thrombolysis during current hospitalization 
 Signed informed consent and expected cooperation of the patient according to ICH/GCP and national/local 
regulations 
 Have a national personal identification number and not be expected to emigrate during study  
 
Exclusion criteria (any of the following) 
 Having a condition where β-blocker-therapy is required, including but not limited to: 
o Arrhythmias 
o Hypertension 
o Cardiomyopathies 
o Clinical diagnosis of heart failure 
o LVEF <40% by echocardiography 
o Significant left ventricular akinesia and/or thrombus formation regardless of the LVEF 
 
 Contraindications to β-blocker-therapy: 
o Brady-arrhythmias 
o Hypotension 
o Severe peripheral artery disease 
o Previously known side-effects causing withdrawal 
o Severe chronic obstructive pulmonary disease 
o Others, according to the responsible investigator 
 Any condition (e.g. psychosis, dementia) or situation, that in the investigators opinion could put the subject at 
significant risk, confound the study results, interfere significantly with the subject participation in the study, or 
rendering informed consent unfeasible 
 Women of childbearing potential using inadequate birth control, pregnancy, and/or breastfeeding. Adequate 
contraception includes oral, injected or implanted hormonal methods of contraception, placement of an 
intrauterine device or system, vasectomized partner or sexual abstinence. 
 Short life expectancy (<1 year) due to non-cardiac co-morbid conditions 
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Table 2 Study data collection  
 Baseline   Treatment period (0-2 years following randomization) End-point 
Time and assessments 
1-8 days 
following 
randomizat
ion 
      Day 30 
Every 6
th
 
month  
Six months     
 
Eighteen 
months 
 
Study-end  
Recruitment, inclusion/exclusion 
evaluation
1)
   
X    
  
Informed consent and 
randomization
2) 
 
X    
  
Collection of relevant hospital 
record data
3)
   
X X            X
*
 
  
Self-reported questionnaires 
(PROMs)
4)
 
X X            X
*
 
  
eCRF (patient self-report)
5)
  X X  
  
Collection of fasting blood samples 
for analyses and biobanking
6)
 
X X
*
            X
*
 
  
Safety assessment obtained from 
medical records and linage to 
national health registries
7)
 
 X  X  
 
X 
 
Assessment of primary and 
secondary study end-points from 
national registries
8)
 
    
  
 
X 
1.   Recruitment and inclusion/exclusion evaluation will be performed at baseline by a dedicated study nurse or  
      the treating physician at PCI centers or community hospitals.  
2.   Randomization and collection of informed consent will be performed at baseline by the treating physician 
or the site-PI. 
3.   Relevant hospital record data at baseline and after 6 months (on a subsample of n=2500) will be registered 
in an eCRF by specially trained study nurses at each site. The following variables will be recorded: Age, 
gender, ethnicity, medical history, index cardiac event (NSTEMI, STEMI), angiographic findings, 
coronary treatment (PCI with or without stent implantation, thrombolysis), electrocardiographic and 
echocardiographic findings (if performed) with emphasis on myocardial function and associated cardiac 
disorders, prescribed medical treatment at discharge, cardiac rehabilitation (content, duration, referral rate) 
and information about  cardiovascular risk factors like  blood pressure, pulse, weight, and height. 
A self-report questionnaire will be completed by all patients at baseline and on a sub-sample (n=2500) 
after 6 months follow-up. The questionnaire comprises lifestyle behaviour (smoking history, physical 
activity), muscle pains (Numeric rating scales 0-10), sexual dysfunction (Female Sexual Function Index 
and The International Index of Erectile Function)  
4.    Symptom burden (New Your Heart Association functional, Canadian Cardiovascular Society functional 
classification of angina), anxiety and depression (the Hospital Anxiety and Depression Scale, PHQ-2), 
Type D personality (DS-14 questionnaire), insomnia (Bergen Insomnia scale, Nightmare Frequency 
Questionnaire and average sleep length), and health-related quality of life (Short Form-12).  
5.  All patients will be complete a brief an electronic questionnaire at day 30 following randomization and 
every 6 months thereafter. The online forms will include brief screening questions covering i. status on β-
blocker treatment and concomitant treatment with antiplatelets, and statins, ii. lifestyle behaviour 
(smoking, physical activity), drug adherence, and perceived drug related side-effects, iii. secondary 
preventive follow-up visits, iv. screening questions on generic health status, depression, anxiety, muscle 
pains, sexual dysfunction, fatigue and insomnia. 
6.  Blood sample collection at baseline and after 6 months follow-up will be performed by the local study 
nurse or a bioengineer. The following non-fasting blood tests will be included: HbA1c, haemoglobin, 
hsCRP, creatinine, cardiac biomarkers (max. Troponin-T/I,), ALT, LDL cholesterol, HDL cholesterol. 
Biobanking for biomarker analyses and pharmacokinetic, pharmacodynamics and pharmacogenetic 
markers will be collected at baseline and after 6 months from both treatment arms on a subgroup of 2500 
patients.  
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7.  Safety data after 30 days will be collected from a standardized telephone interview with all patients. The 
screening questions include occurrence of events since discharge, particularly hospitalizations for 
subsequent cardiovascular events or reiteration of study proceduresThe hospital records will be reviewed 
by the sitePI if patients report hospitalization for subsequent cardiovascular events on the telephone 
interview.  Satefy assessment after 6 and 18 moths follow-up include non-fatal MI and all-cause death 
collected from the Norwegian Cardiovascular Disease Registry and the Norwegian Population Registry.  
8. The primary and secondary study end-points will be obtained at study end by linking study data to 
administrative registries (income, social security micro data, healthcare utilization, drug prescription) and 
clinical CVD (myocardial infarction, heart failure, arrhythmias, coronary angiography) registries and the 
Cause of Death Registry after patient enrollment is completed. 
ACCEPTED MANUSCRIPT
Figure 1
